The American Journal of Managed Care7h
Studies Highlight Prognostic Value of Neutrophil-to-Lymphocyte Ratio in MPNs
Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...
Daily16h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz20h
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Yahoo Finance1d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
EurekAlert!1d
Sylvester Cancer researchers share findings in oral presentations at the ASH 2024 Annual Meeting & Exposition
Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained ...
Yahoo Finance2d
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...
Business Wire3d
Geron to Participate in the Stifel 2024 Healthcare Conference
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...
GlobalData on MSN3d
Disc Medicine secures $200m financing to support trials
The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available ...
The American Journal of Managed Care4d
Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Too Old to Operate6d
Navigating Challenges in HSCT Eligibility for Myelofibrosis
Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
Promising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data Releases
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...